Key clinical point: Five serum markers – beta-defensin 2, lipocalin 2, interleukin-22, IL-8, and calprotectin – may detect systemic inflammation in patients with psoriatic disease who do not have elevated C-reactive protein.
Major finding: Two markers were elevated in a majority of patients with monomorphic skin and entheseal disease. Another two markers were elevated in a majority of patients with joint disease. IL-22 was elevated in skin, entheseal, and joint disease.
Study details: A cross-sectional study of 105 healthy controls and 105 patients with psoriatic disease and a subsequent longitudinal study of 20 patients with psoriatic arthritis.
Disclosures: The study was supported by the German Research Foundation and other grant and fellowship funding. The authors had no competing interests.
Sokolova MV et al. Arthritis Res Ther. 2020;22:26.